Evidence map›Paper›PMID 31048360›Full record

ArticleMolecular systems biology2019

Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection.

Srivamshi Pittala, Kenneth Bagley, Jennifer A Schwartz, Eric P Brown, Joshua A Weiner, Ilia J Prado, Wenlei Zhang, Rong Xu, Ayuko Ota-Setlik, Ranajit Pal and 12 more

Open access · goldAbstract read
In one paragraph

Article in Molecular systems biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Science immunology · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 1 country.

Srivamshi PittalaDepartment of Computer Science, Dartmouth, Hanover, NH, USA.
Kenneth BagleyProfectus BioSciences, Inc., Baltimore, MD, USA.
Jennifer A SchwartzProfectus BioSciences, Inc., Baltimore, MD, USA.
Eric P BrownThayer School of Engineering, Dartmouth, Hanover, NH, USA.
Joshua A WeinerThayer School of Engineering, Dartmouth, Hanover, NH, USA.
Ilia J PradoProfectus BioSciences, Inc., Baltimore, MD, USA.
Wenlei ZhangProfectus BioSciences, Inc., Baltimore, MD, USA.
Rong XuProfectus BioSciences, Inc., Baltimore, MD, USA.
Ayuko Ota-SetlikProfectus BioSciences, Inc., Baltimore, MD, USA.
Ranajit PalAdvanced Bioscience Laboratories, Inc., Rockville, MD, USA.
Xiaoying ShenDuke Human Vaccine Institute, Durham, NC, USA.
Charles BeckDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Guido FerrariDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
George K LewisInstitute for Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-4815-2604
Celia C LaBrancheDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
David C MontefioriDuke University, Durham, NC, USA.
Georgia D TomarasDuke Human Vaccine Institute, Durham, NC, USA.
Galit AlterHarvard Medical School, Boston, MA, USA.
Mario RoedererVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Timothy R FoutsProfectus BioSciences, Inc., Baltimore, MD, USA.
Margaret E AckermanThayer School of Engineering, Dartmouth, Hanover, NH, USA.ORCID 0000-0002-4253-3476
Chris Bailey-KelloggDepartment of Computer Science, Dartmouth, Hanover, NH, USA cbk@cs.dartmouth.edu.ORCID 0000-0003-1860-0912
Profectus Biosciences (United States) · USDartmouth College · USDuke Medical Center · USAdvanced Bioscience Laboratories (United States) · USDuke University · USHarvard University · USUniversity of Maryland, Baltimore · US

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
Physical Resources CoreP01AI120756 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2016 to 2020
$17.1M
Functional And Phenotypic Characterization Of T Cells In ManZIAAI005021 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ROEDERER, MARIO · 2009 to 2022
$14.4M
Project 3- Mucosal Determinants of Virus TransmissionP01AI124912 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI GALLO, ROBERT C · 2016 to 2019
$14.4M
Monoclonal antibody isolation and characterizationZIAAI005126 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MASON, ROSEMARIE · 2015 to 2025
$10.1M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
Tuning Fc-effector functions of HIV-specific antibodiesR01AI102660 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2012 to 2015
$3.0M
Optimization of a DNA Subunit Regimen for an HIV VaccineR44AI102702 · NIAID · PROFECTUS BIOSCIENCES, INC. · PI BAGLEY, KENNETH C · 2012 to 2015
$2.9M
Directing Antibody Effector Activity via Controlled IgG Subclass SwitchingR01AI131975 · NIAID · DARTMOUTH COLLEGE · PI ACKERMAN, MARGARET E · 2017 to 2020
$2.6M
Enhancing DNA vaccines using modified Bacterial Toxin A1 Subunits as adjuvantsR44AI074334 · NIAID · PROFECTUS BIOSCIENCES, INC. · PI FOUTS, TIMOTHY R · 2010 to 2012
$2.4M
Preclinical Development of Full Length Single ChainR44AI091567 · NIAID · PROFECTUS BIOSCIENCES, INC. · PI FOUTS, TIMOTHY R · 2010 to 2012
$2.3M
NIAID NIH HHS HHSN272201100016CNIAID NIH HHS P01 AI120756NIAID NIH HHS P01 AI124912NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI102660NIAID NIH HHS R01 AI131975NIAID NIH HHS R37 AI080289NIAID NIH HHS R44 AI074334NIAID NIH HHS R44 AI091567NIAID NIH HHS R44 AI102702
6 · The paper itself

Abstract

Characterizing the antigen-binding and innate immune-recruiting properties of the humoral response offers the chance to obtain deeper insights into mechanisms of protection than revealed by measuring only overall antibody titer. Here, a high-throughput, multiplexed Fab-Fc Array was employed to profile rhesus macaques vaccinated with a gp120-CD4 fusion protein in combination with different genetically encoded adjuvants, and subsequently subjected to multiple heterologous simian immunodeficiency virus (SIV) challenges. Systems analyses modeling protection and adjuvant differences using Fab-Fc Array measurements revealed a set of correlates yielding strong and robust predictive performance, while models based on measurements of response magnitude alone exhibited significantly inferior performance. At the same time, rendering Fab-Fc measurements mathematically independent of titer had relatively little impact on predictive performance. Similar analyses for a distinct SIV vaccine study also showed that Fab-Fc measurements performed significantly better than titer. These results suggest that predictive modeling with measurements of antibody properties can provide detailed correlates with robust predictive power, suggest directions for vaccine improvement, and potentially enable discovery of mechanistic associations.

Indexed as

AnimalsAntibodies, ViralCD4-Positive T-LymphocytesHumansImmunity, HumoralImmunoglobulin FragmentsImmunoglobulin GMacaca mulattaMembrane GlycoproteinsMultivariate AnalysisSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral Envelope ProteinsAntibodies, Viralgp120 protein, Simian immunodeficiency virusImmunoglobulin FragmentsImmunoglobulin GMembrane GlycoproteinsSAIDS VaccinesViral Envelope Proteinsantibody effector functionbiomarker identificationHIVprotection modelingsystems serology

Identifiers

PMID31048360
PMCPMC6497031
OpenAlexW2942765343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.